Journal
ONCOLOGY LETTERS
Volume 22, Issue 6, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2021.13117
Keywords
haematological; malignancies; cancer; COVID-19; pandemic; translational genetics; healthcare services; SARS-CoV-2
Categories
Funding
- European and Developing Countries Clinical Trials Partnership (EDCTP2) under the Horizon 2020 'Research and Innovation Actions' DESCA [RIA2018EF-2081]
- European Regional Development Fund of the European Union
- Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE [T2EDK-02222]
Ask authors/readers for more resources
The COVID-19 pandemic has worsened healthcare services for cancer patients, especially those with haematological malignancies. Clinicians are facing challenges in maintaining productivity while adhering to strict policies to prevent virus transmission. Improvements in healthcare services are crucial not only for the current pandemic but also for future management of patients in potential pandemics.
The COVID-19 pandemic has complicated current healthcare services for cancer patients. Patients with haematological malignancies specifically seem vulnerable to SARS-CoV-2 infection due to their immunosuppressed status. The COVID-19 pandemic influences every step of the assessment and treatment of a haematological malignancy. Clinicians must adhere to strict policies to not spread the virus to their patients while they must also adjust their workflow for maximum productivity. These difficulties accentuate the ever-present need to improve the healthcare services for cancer patients. This improvement is needed not only to combat the problems that arose from the COVID-19 pandemic but also to establish a framework for the management of patients with haematological malignancies in potential future pandemics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
